Cargando…
The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs
A vaccine that prevents hepatitis C virus (HCV) infection is urgently needed to support an emerging global elimination program. However, vaccine development has been confounded because of HCV's high degree of antigenic variability and the preferential induction of type‐specific immune responses...
Autores principales: | Vietheer, Patricia T., Boo, Irene, Gu, Jun, McCaffrey, Kathleen, Edwards, Stirling, Owczarek, Catherine, Hardy, Matthew P., Fabri, Louis, Center, Rob J., Poumbourios, Pantelis, Drummer, Heidi E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408392/ https://www.ncbi.nlm.nih.gov/pubmed/27997681 http://dx.doi.org/10.1002/hep.28989 |
Ejemplares similares
-
Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region
por: Alhammad, Yousef, et al.
Publicado: (2015) -
Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine‐induced neutralizing activity
por: Kachko, Alla, et al.
Publicado: (2015) -
Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes
por: Gu, Jun, et al.
Publicado: (2018) -
Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance
por: di Iulio, Julia, et al.
Publicado: (2011) -
Histological changes in HCV antibody–positive, HCV RNA–negative subjects suggest persistent virus infection
por: Hoare, Matthew, et al.
Publicado: (2008)